

Phase 2				
Enrollment/ Leukapheresis	Optional Bridging Therapy ^a	Conditioning Chemotherapy	CAR T-Cell Dose	Follow-up Period
R/R MCL (1-5 prior lines of therapy)	Dexamethasone 20-40 mg or equivalent PO or IV daily for 1-4 days, or ibrutinib 560 mg PO daily, or acalabrutinib 100 mg PO twice daily	Fludarabine 30 mg/m ² IV and cyclophosphamide 500 mg/m ² IV on Days -5, -4, -3	2x10 ⁶ cells/kg KTE-X19 single IV infusion on Day 0	First tumor assessment on Day 28 ^b
Of 60 patients in ZUMA-2 with MCL treated with KTE-X19 with a median follow-up of 17.5 months⁵ • 92% ORR • 67% CR rate • 48% of all patients and 70% of patients in CR in ongoing response at data cutoff			CRS and neurologic events were mostly reversible (N=68 treated patients)^{4,5} • 15% Grade ≥3 CRS; 31% Grade ≥3 neurologic events • 2 Grade 5 AEs (1 KTE-X19-related) • No new safety signals observed with longer follow- up	

FIG. 1




FIG. 2




FIG. 3A




FIG. 3B






FIG. 3C




CAR T-cell levels peaked within 14 days posttreatment.
^aCAR T-cell levels assessed for Days 0 to 28.
AUC, area under the curve; CAR, chimeric antigen receptor; with POD24, progression of disease <24 months after initial diagnosis; without POD24, progression of disease $\geq$ 24 months after initial diagnosis.

FIG. 4



With POD24, progression of disease <24 months after initial diagnosis; without POD24, progression of disease ≥24 months after initial diagnosis.

FIG. 5



Key ZUMA-5 Eligibility Criteria

- R/R FL (Grades 1-3a) or MZL (nodal or extranodal)^a
- ≥2 Prior lines of therapy that must have included an anti-CD20 mAb combined with an alkylating agent^b

Patients and Analysis

- The updated efficacy analysis occurred when ≥80 treated patients with FL had ≥18 months of follow-ups^c
- Data cutoff date: September 14, 2020
- Axi-cel-treated patients with FL or MZL and available data on progression after an anti-CD20 mAb + alkylating agent were included in the POD24 analysis (N=129)

FIG. 6




FIG. 7




FIG. 8A





FIG. 8B






FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10A




FIG. 10C

FIG. 10B




FIG. 10E

FIG. 10D




FIG. 11




FIG. 12



TO FIG. 12 (CONT.)

